Company Filing History:
Years Active: 2010
Title: Meijia Yang: Innovator in Hybrid Antigen Binding Molecules
Introduction
Meijia Yang is a prominent inventor based in Scituate, MA (US). She has made significant contributions to the field of biotechnology, particularly in the development of hybrid antigen binding molecules. Her innovative work has the potential to impact both diagnosis and therapy in various medical applications.
Latest Patents
Meijia Yang holds a patent for "Compositions and methods of producing hybrid antigen binding molecules and uses thereof." This patent relates to hybrid antigen binding molecules that include at least two polypeptide chains, with at least one chain comprising an antigen binding moiety linked to an amino acid sequence of a subunit of a heterodimeric proteinaceous hormone. The patent also discloses methods for making and using these hybrid molecules for diagnostic and therapeutic purposes. She has 1 patent to her name.
Career Highlights
Meijia Yang is currently employed at Merck Serono S.A., where she continues to advance her research in the field of biotechnology. Her work at Merck Serono has allowed her to collaborate with leading experts and contribute to groundbreaking innovations.
Collaborations
Some of her notable coworkers include Sean D. McKenna and Robert K. Campbell. Their collaborative efforts have further enhanced the research and development of hybrid antigen binding molecules.
Conclusion
Meijia Yang is a trailblazer in the field of biotechnology, with her innovative patent on hybrid antigen binding molecules showcasing her expertise and dedication. Her contributions are poised to make a lasting impact on medical diagnostics and therapies.